ORIC Pharmaceuticals, Inc. Form 8-K Summary
Reporting date: March 23, 2021. The filing reports that ORIC Pharmaceuticals issued a press release covering financial results for the fourth quarter and full year ended December 31, 2020.
Business Context and Reporting Period
ORIC Pharmaceuticals is a Delaware-incorporated biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under the symbol ORIC. The company furnished this report under Item 2.02 and attached the related press release as Exhibit 99.1.
Financial Results and Liquidity
The filing text provided does not include the financial results contained in the referenced press release. Accordingly, revenue, net loss or profit, operating expenses, cash flow, cash and investments, margins, debt, liquidity, and cash runway are not clearly stated in the supplied text.
Material Changes Versus Prior Period
The filing identifies results for the fourth quarter and full year ended December 31, 2020, but does not provide comparative figures or describe material changes versus the prior comparable periods.
Guidance, Outlook, Risks, and Unusual Items
No guidance, outlook, management commentary, risk updates, contingencies, or unusual items are included in the supplied filing text. These matters may have been addressed in Exhibit 99.1, but the exhibit content was not provided.
Important Facts to Verify
- Verify the complete March 23, 2021 press release, Exhibit 99.1, for fourth-quarter and full-year 2020 financial metrics.
- Verify year-over-year changes in operating expenses, net loss, cash position, and cash runway.
- Verify any clinical-development updates, forward guidance, financing plans, or risk disclosures in the attached press release.
- Note that the information under Items 2.02 and 9.01, including Exhibit 99.1, was furnished and is not deemed filed for Section 18 liability purposes unless expressly incorporated by reference.